

Candida antigen safe, effective for treating common warts

August 21 2017



(HealthDay)—*Candida* antigen is a promising, effective, and safe

immunotherapeutic treatment for common warts, according to a study published online Aug. 8 in the *International Journal of Dermatology*.

Ahmad Nofal, M.D., from Zagazig University in Egypt, and colleagues evaluated the efficacy and safety of *Candida* antigen for the treatment of common warts and the significance of [interferon gamma](#) (IFN- γ) in the prediction of successful therapy. Blood samples were collected from 54 patients with multiple common warts before therapy, cultured, and treated with *Candida* antigen for evaluation of IFN- γ . Direct injections of *Candida* antigen were made into the largest wart at two-week intervals until complete clearance or for a maximum of five treatments.

The researchers found that complete clearance of the lesions was seen in 61.1 percent of the studied patients. Among cases that responded, IFN- γ was statistically higher, compared to that seen in non-responders. No significant adverse effects or recurrence of warts was observed.

"*Candida* antigen is a promising, effective, and safe immunotherapeutic modality for common warts, and IFN- γ may serve as a good predictor of its therapeutic response," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: *Candida* antigen safe, effective for treating common warts (2017, August 21) retrieved 25 April 2024 from <https://medicalxpress.com/news/2017-08-icandidai-antigen-safe-effective-common.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--